Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 7/20 | 0.39 |
| ▸ | DRD1 | P21728 | 6/20 | 0.39 |
| ▸ | DRD4 | P21917 | 6/20 | 0.39 |
| ▸ | DRD5 | P21918 | 6/20 | 0.39 |
| ▸ | DRD3 | P35462 | 6/20 | 0.39 |
| ▸ | DRD2 | P14416 | 8/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL589584 | 0.75 | HTR1A (0.42) | ABCB1HTR1ADRD1DRD4DRD5 | |
| SCHEMBL3167361 | 0.75 | ABCB1 (0.39) | ABCB1HTR1ADRD1DRD4DRD5 | |
| SCHEMBL3177932 | 0.70 | HTR1A (0.43) | ABCB1HTR1ADRD1DRD4DRD5 | |
| SCHEMBL3162952 | 0.69 | HTR1A (0.43) | HTR1ADRD1DRD4DRD5DRD3 | |
| SCHEMBL27571659 | 0.65 | DRD2 (0.57) | ABCB1HTR1ADRD1DRD4DRD5 | |
| SCHEMBL10810455 | 0.63 | DRD2 (0.40) | DRD1DRD4DRD5DRD3DRD2 | |
| SCHEMBL10814511 | 0.63 | DRD2 (0.40) | DRD1DRD4DRD5DRD3DRD2 | |
| SCHEMBL256656 | 0.62 | DRD2 (0.78) | HTR1ADRD1DRD4DRD5DRD3 | |
| SCHEMBL8920612 | 0.62 | ABCB1 (0.50) | ABCB1HTR1ADRD3DRD2GNAI3 | |
| SCHEMBL11939035 | 0.62 | DRD2 (0.83) | HTR1ADRD1DRD5DRD3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155192-B1 | TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS | STERIX LTD (GB) | 2016-09-28 | — | — | EP | disclosed |
| US-8394825-B2 | Compound | STERIX LIMITED (GB) | 2013-03-12 | — | — | US | disclosed |
| US-20100222299-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-09-02 | — | — | US | disclosed |
| EP-2155192-A2 | TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS | Sterix Limited (GB) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008117061-A2 | TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS | STERIX LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222299-A1 | COMPOUND | MKI67, VHL, MYC | ABCB1 754/4885HTR1A 1761/4885DRD1 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.